According to The Insight Partners' research, the Middle East and Africa Injectable Drug Delivery Market was valued at US$ 935.4 Million in 2024 and is expected to reach US$ 1,433.8 Million by 2031, registering a CAGR of 6.4% from 2025 to 2031.
Advancing lipid nanoparticle injectables for rapid-response vaccines and gene editing and use of biodegradable polymers & green packaging in Injectable Drug Systems are among the critical factors driving the growth of injectable drug delivery market.
mRNA-based therapies delivered via lipid nanoparticles (LNPs) offer scalable, customizable platforms for vaccines, gene editing, and regenerative medicine. Projections indicate widespread adoption by 2035 to address emerging pandemics and genetic disorders. LNPs, refined through ionizable lipids and PEG modifications, facilitate endosomal escape for cytosolic mRNA release post-intramuscular injection. In 2025, FDA approvals for LNP-encapsulated mRNA targeting liver diseases, such as alpha-1 antitrypsin deficiency, achieved 80% protein expression in hepatocytes. This evolution from COVID-19 vaccines, which protected over 13 billion doses globally by 2023, extends to non-viral applications. OS4T LNPs crossed the blood-brain barrier in glioblastoma models, delivering mRNA for CAR-T cell therapy and extending survival by 25% in murine studies. NIH research highlights LNPs' versatility, with design strategies enabling dose-sparing formulations that reduce injection volumes by 50%, crucial for pediatric and elderly populations. As per WHO data, infectious diseases caused 15 million deaths in 2021, with mRNA injectables potentially averting 70% of future outbreaks through rapid manufacturing-under 100 days versus years for traditional vaccines. Future iterations will incorporate brain-penetrating LNPs for neurological conditions, tuning physicochemical properties to minimize inflammation and enhance immunogenicity. Regulatory advancements, including EMA's 2025 guidelines for LNP immunogenicity profiling, will accelerate approvals. Challenges such as cold-chain dependency spur thermostable variants. By democratizing gene therapies in low-income regions, where 90% of genetic disorders go untreated, this trend could save billions in healthcare costs and transform preventive care, heralding an era of on-demand injectables.
On the flipside, stringent regulatory requirements and protracted approval processes hamper the injectable drug delivery market growth.
Middle East and Africa Injectable Drug Delivery Market Segmentation Analysis:
- By Device Type, the Middle East and Africa Injectable Drug Delivery Market is segmented into Conventional Drug Delivery Devices and Advanced Drug Delivery Devices. The Conventional Drug Delivery Devices segment is projected to expand at a CAGR of 5.3% during 2025 - 2031.
- By Formulation, the Middle East and Africa Injectable Drug Delivery Market is segmented into Conventional Drug Delivery, Novel Drug Delivery, and Long Acting Injectable Formulations. The Conventional Drug Delivery segment is projected to expand at a CAGR of 5.9% during 2025 - 2031.
- By Formulation Packaging, the Middle East and Africa Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment is projected to expand at a CAGR of 6.2% during 2025 - 2031.
- By Therapeutic Application, the Middle East and Africa Injectable Drug Delivery Market is segmented into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Other Therapeutic Application. The Diabetes segment is projected to expand at a CAGR of 6.6% during 2025 - 2031.
- By Route of Administration, the Middle East and Africa Injectable Drug Delivery Market is segmented into Sub-cutaneous, Intramuscular, Intravenous, and Other Route of Administration. The Sub-cutaneous segment is projected to expand at a CAGR of 6.5% during 2025 - 2031.
- By Usability, the Middle East and Africa Injectable Drug Delivery Market is segmented into Disposable Injectors and Re-usable Injectors. The Disposable Injectors segment is projected to expand at a CAGR of 5.1% during 2025 - 2031.
- By End User, the Middle East and Africa Injectable Drug Delivery Market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. The Pharmaceutical and Biopharma Companies segment is projected to expand at a CAGR of 5.1% during 2025 - 2031.
By country, the Middle East and Africa Injectable Drug Delivery Market is categorized into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. South Africa is projected to expand at a CAGR of 7.0% during 2025 - 2031.
Key players operating in the Injectable Drug Delivery Market are B Braun SE, Terumo Corp, Cardinal Health Inc, Phillips-Medisize, Nipro Corp, Gerresheimer AG, West Pharmaceutical Services Inc, Schott AG, Becton Dickinson and Co, Kindeva Drug Delivery LP, among others.
2025: West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced the launch of its West Synchrony Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026.
2024: Nipro and Owen Mumford partnered to distribute drug delivery device, UniSafe. The biosimilar product is delivered through Owen Mumfords UniSafe safety syringe, which is a springless and passive safety device for 1mL pre-filled syringes.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com